product:clopidogrel

  • Heartburn Drugs Linked to Heart Attacks - NYTimes.com
    http://well.blogs.nytimes.com/2015/06/10/gastric-reflux-drugs-linked-to-heart-attacks

    Previous studies have found that P.P.I.’s are associated with poor outcomes for people with heart disease, probably because of an interaction with clopidogrel, a drug commonly prescribed after a heart attack. This new study examines the heart attack risk in otherwise healthy people.

    The researchers used data-mining, a mathematical method of looking at trends in large amounts of data, to analyze the use of the drugs over time. Evidence that they were increasing the risk for heart attack was clear as early as 2000.

    “This is the kind of analysis now possible because electronic medical records are widely available,” said the lead author, Nigam H. Shah, an assistant professor of medicine at Stanford. “It’s a benefit of the electronic records system that people are always talking about.”

    There was no association of heart attack with another class of drugs used to treat gastric reflux, H2 blockers like Zantac, Tagamet and Pepcid. The researchers suggest that P.P.I.’s promote inflammation and clots by interfering with the actions of protective enzymes.

    A significant limitation of the study, in PLOS One, is that P.P.I. usage may be a marker of a sicker patient population, more subject to heart disease in any case.

    #IPP #santé

  • Major personalised medicine test may be pointless
    http://blogs.nature.com/news/2011/12/major-personalised-medicine-test-may-be-pointless.html

    personalised medicine now has a “cult like following” in the media and while it has produced benefits in areas such as breast cancer and has a bright future “overzealous adoption based on limited biochemical data” is not in the public interest.

    The #FDA estimates the cost of genetic testing to be between $60 and $500 and clopidogrel is used by some 40 million people around the world, according to the JAMA papers.

    “The consequences of the FDA’s leap to judgement regarding CYP2C19 cannot be underestimated,” Nissen writes.

    #médecine #génétique #santé #gâchis #médias